TARS

Business Context and Reporting Period

Tarsus Pharmaceuticals, Inc. (TARS) is a commercial-stage biopharmaceutical company focused on eye care and infectious disease prevention. The reporting period covers the fiscal year ended December 31, 2025. The Company's primary revenue driver is XDEMVY (lotilaner ophthalmic solution) 0.25%, the first and only FDA-approved therapeutic for Demodex blepharitis, launched in August 2023. The Company maintains a pipeline including TP-04 for ocular rosacea and TP-05 for Lyme disease prophylaxis.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 147% year-over-year, driven by a 151% increase in net product sales of XDEMVY. Sales volume rose to approximately 400,000 bottles in 2025 compared to 163,000 in 2024.
• Expense Expansion: Operating expenses increased 72% to $522.3 million. Selling, general, and administrative (SG&A) expenses surged 80% to $427.3 million, primarily due to a $112.6 million increase in commercial and marketing costs, including direct-to-consumer (DTC) advertising.
• Improved Profitability: Net loss narrowed by 43% to $66.4 million, reflecting revenue growth outpacing expense increases.
• License Revenue: License fees and collaboration revenue dropped to zero in 2025 from $2.9 million in 2024, as the prior year included one-time termination and warrant cancellation payments related to the China Out-License transition.

Guidance, Outlook, and Risks

Outlook and Pipeline: Management believes current cash resources ($417.3 million) are sufficient to fund operations for at least the next 12 months. Key milestones include the initiation of a Phase 2 trial for TP-05 (Lyme disease) in Q2 2026 and expected topline results for the TP-04 (ocular rosacea) Phase 2 trial in the first half of 2027. International expansion is underway, with potential approval expected in China in 2026 and Europe in 2027.

Management Commentary: The Company highlighted a successful DTC campaign that increased unaided awareness of Demodex blepharitis from 2% to 25%. Gross-to-net discounts stabilized at approximately 45% for the full year 2025.

Risks and Contingencies:

• Single Product Dependence: The Company relies entirely on XDEMVY for revenue; failure to maintain market acceptance or pricing could materially harm operations.
• Regulatory and Pricing: Risks include potential FDA enforcement actions regarding DTC advertising, changes in Medicare Part D reimbursement under the Inflation Reduction Act, and pricing pressures.
• Supply Chain: Reliance on single-source suppliers for the active pharmaceutical ingredient (lotilaner) and contract manufacturers creates supply chain vulnerability.
• Intellectual Property: The Company's pipeline depends on licenses from Elanco; termination of these agreements would halt development.

Investor Verification Checklist

• Reimbursement Trends: Verify the sustainability of the 45% gross-to-net discount and payer coverage rates (currently >90%) in light of evolving Medicare Part D rules.
• Marketing Efficiency: Assess the return on investment (ROI) of the $121.2 million spent on advertising in 2025 and the correlation with the 25% unaided awareness metric.
• Supply Chain Resilience: Confirm the status of qualifying a second manufacturer for lotilaner to mitigate single-source risk.
• China Partnership: Monitor the progress of GrandPharma's development of TP-03 in China and the likelihood of achieving the remaining $120 million in potential milestones.
• Cash Burn Rate: Evaluate the $12.5 million net cash used in operating activities against the $417.3 million cash balance to validate the 12-month liquidity runway.